SCHEMBL393318

SCHEMBL393318

COC(=O)c1ccc(Br)cc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.51
ABL1 P00519 1/20 0.50
HPGD P15428 3/20 0.49
FLT1 P17948 1/20 0.48
FLT4 P35916 1/20 0.48
KDR P35968 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
ABCG2 Q9UNQ0 1/20 0.47
GAA P10253 3/20 0.47
ALDH1A1 P00352 2/20 0.47
SLC6A3 Q01959 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
PDK2 Q15119 1/20 0.46
PDK4 Q16654 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29849280 0.85 HPGD (0.60) NR4A2HPGDGAAALDH1A1POLB
SCHEMBL195401 0.85 HPGD (0.60) NR4A2HPGDGAAALDH1A1POLB
SCHEMBL335673 0.83 NPC1 (0.56) NR4A2ABL1HPGDALDH1A1CA12
SCHEMBL23380259 0.82 PDK2 (0.50) NR4A2ABL1HPGDFLT1FLT4
SCHEMBL29773857 0.82 NR4A2 (0.56) NR4A2ABL1HPGDL3MBTL1ABCG2
SCHEMBL4577829 0.82 NR4A2 (0.56) NR4A2ABL1HPGDL3MBTL1ABCG2
SCHEMBL3839211 0.81 NR4A2 (0.54) NR4A2ABL1HPGDFLT1FLT4
SCHEMBL608814 0.81 ABL1 (0.68) NR4A2ABL1HPGDFLT1FLT4
SCHEMBL2884923 0.81 PDK2 (0.57) ABL1HPGDL3MBTL1GAAALDH1A1
SCHEMBL7219321 0.81 ALDH1A1 (0.42) HPGDFLT1FLT4KDRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 357 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof LG CHEM, LTD. (KR) 2026-05-26 US disclosed
EP-4076460-B1 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER MERCK SHARP & DOHME LLC (US) 2026-01-21 EP disclosed
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-25 US disclosed
US-12503439-B2 Heteroaryl compounds for the treatment of pain VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-23 US disclosed
US-12441730-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2025-10-14 US disclosed
US-20250223291-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS INCYTE CORPORATION 2025-07-10 US disclosed
WO-2025122491-A1 FUSED BICYCLIC ARYL COMPOUNDS FOR BORON NEUTRON CAPTURE THERAPY AVIKO RADIOPHARMACEUTICALS, LLC (US) 2025-06-12 WO disclosed
CN-119677737-A Heteroaryl compounds for the treatment of pain 沃泰克斯药物股份有限公司 2025-03-21 CN disclosed
CN-119546580-A Heteroaryl compounds for the treatment of pain 沃泰克斯药物股份有限公司 2025-02-28 CN disclosed
EP-4511116-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 EP disclosed
EP-1000012-A1 PROCESS FOR CONVERTING PROPARGYLIC AMINE-N-OXIDES TO ENAMINONES AMERICAN HOME PRODUCTS CORPORATION (US) 2000-05-17 EP disclosed
EP-1000059-A1 TRICYCLIC VASOPRESSIN AGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-05-17 EP disclosed
EP-0995742-A1 SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-26 EP disclosed
EP-0971894-A1 NICOTINAMIDE DERIVATIVES Pfizer Products Inc. (US) 2000-01-19 EP disclosed
WO-1999065877-A1 THERAPEUTIC BIARYL DERIVATIVES GLAXO GROUP LIMITED (GB) 1999-12-23 WO disclosed
US-5932745-A HYDROXYLIC SOLVENT AMERICAN HOME PRODUCTS CORPORATION (US) 1999-08-03 US disclosed
WO-1999006403-A1 TRICYCLIC VASOPRESSIN AGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 1999-02-11 WO disclosed
WO-1999006351-A1 PROCESS FOR CONVERTING PROPARGYLIC AMINE-N-OXIDES TO ENAMINONES AMERICAN HOME PRODUCTS CORPORATION (US) 1999-02-11 WO disclosed
US-5856574-A ANTIISCHEMIC AGENTS; ANTIARRTHYMIA AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1999-01-05 US disclosed
WO-1998045268-A1 NICOTINAMIDE DERIVATIVES PFIZER PRODUCTS INC. (US) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN SCN8A, SCN1B, SCN3A NR4A2 421/4885ABL1 1619/4885HPGD 2534/4885
US-20250223291-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS ERBB2, MERTK, ABL1 NR4A2 800/4885ABL1 3/4885HPGD 4588/4885
US-12503439-B2 Heteroaryl compounds for the treatment of pain TRPV1, SCN3A, KCNN3 NR4A2 2419/4885ABL1 739/4885HPGD 546/4885
US-12441730-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT3 NR4A2 3706/4885ABL1 433/4885HPGD 1246/4885
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof DGAT2, DGAT1, DLAT NR4A2 2151/4885ABL1 650/4885HPGD 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.